Compare ALNT & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | FTRE |
|---|---|---|
| Founded | 1962 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 903.4M | 864.4M |
| IPO Year | N/A | N/A |
| Metric | ALNT | FTRE |
|---|---|---|
| Price | $54.52 | $14.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 8 |
| Target Price | ★ $50.33 | $11.64 |
| AVG Volume (30 Days) | 170.0K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ 28.52 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | $533,134,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $4.80 | $3.17 |
| Revenue Next Year | $5.42 | $0.04 |
| P/E Ratio | $48.66 | ★ N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $19.25 | $3.97 |
| 52 Week High | $58.13 | $23.97 |
| Indicator | ALNT | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 69.75 |
| Support Level | $51.90 | $12.12 |
| Resistance Level | $55.36 | $14.96 |
| Average True Range (ATR) | 2.36 | 0.97 |
| MACD | 0.20 | 0.30 |
| Stochastic Oscillator | 79.74 | 88.66 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty motion control components and systems. The firm primarily caters to the vehicle, medical, aerospace and defense, and electronics and industrial, pumps, and robotics sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.